List of Excipients in Branded Drug EDARBI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Azurity Pharmaceuticals Inc	EDARBI	azilsartan kamedoxomil	60631-040	CELLULOSE, MICROCRYSTALLINE
Azurity Pharmaceuticals Inc	EDARBI	azilsartan kamedoxomil	60631-040	CROSCARMELLOSE SODIUM
Azurity Pharmaceuticals Inc	EDARBI	azilsartan kamedoxomil	60631-040	FUMARIC ACID
Azurity Pharmaceuticals Inc	EDARBI	azilsartan kamedoxomil	60631-040	HYDROXYPROPYL CELLULOSE
Azurity Pharmaceuticals Inc	EDARBI	azilsartan kamedoxomil	60631-040	MAGNESIUM STEARATE
Azurity Pharmaceuticals Inc	EDARBI	azilsartan kamedoxomil	60631-040	MANNITOL
Azurity Pharmaceuticals Inc	EDARBI	azilsartan kamedoxomil	60631-040	SODIUM HYDROXIDE

EDARBI Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

EDARBI is a small-molecule antihypertensive containing azilsartan medoxomil, an oral prodrug of azilsartan. Its commercial opportunity is concentrated in generic tablet development, differentiated oral dosage forms, fixed-dose combinations, and excipient systems that improve manufacturability without creating unnecessary regulatory or patent risk. The current product uses a relatively simple immediate-release tablet formulation, leaving room for formulation suppliers and generic manufacturers to compete on cost, robustness, patient convenience, and lifecycle management.

What is EDARBI and which excipients does it contain?

EDARBI is approved in the United States for the treatment of hypertension in adults and children at least six years old. The approved adult dose is 80 mg once daily; 40 mg is recommended for patients receiving high-dose diuretics. The active ingredient is azilsartan medoxomil, which is hydrolyzed to azilsartan during absorption and metabolism.[1]

The FDA labeling identifies the principal inactive ingredients as mannitol, fumaric acid, and sodium hydroxide. The commercial tablet also uses standard film-coating components. The precise composition and supplier grades are not fully disclosed in the public label.[1]

Product attribute	EDARBI profile
Active ingredient	Azilsartan medoxomil
Therapeutic class	Angiotensin II receptor blocker
Dosage form	Immediate-release oral tablet
U.S. approval	2011
U.S. NDA	NDA 200796
Adult dosing	40 mg or 80 mg once daily
Pediatric use	Approved for patients six years and older
Principal disclosed excipients	Mannitol, fumaric acid, sodium hydroxide
Primary regulatory pathway for generics	ANDA
Biosimilar relevance	None; EDARBI is a small-molecule product

The formulation is commercially important because it avoids a complex modified-release platform. A generic manufacturer can pursue a conventional immediate-release tablet, but it must still match critical quality attributes, dissolution behavior, impurity limits, stability, and bioequivalence requirements.

What excipient strategy does EDARBI use?

EDARBI’s disclosed excipient system appears designed around tablet manufacturability, chemical stability, and acceptable oral performance rather than a high-complexity delivery technology.

Mannitol

Mannitol can function as a diluent and tabletability aid. It is widely used in oral solid dosage forms and can support acceptable mouthfeel, low hygroscopicity relative to some polyols, and improved processing characteristics. For a low-dose or moderate-dose tablet, mannitol can help create a robust tablet mass while limiting excessive moisture uptake.

Commercial implications include:

• Demand for direct-compression or granulation-grade mannitol.
• Opportunity for suppliers to offer controlled particle-size distributions.
• Potential substitution studies involving lactose, microcrystalline cellulose, dibasic calcium phosphate, or other fillers.
• Need to control polymorphic form, particle morphology, density, and moisture.

A supplier seeking to replace EDARBI’s mannitol should expect the change to affect blend uniformity, compression force, tablet tensile strength, disintegration, and dissolution.

Fumaric acid

Fumaric acid may contribute to microenvironmental pH control and formulation stability. Acidic excipients are often used to influence degradation pathways, especially where the active ingredient or prodrug has pH-dependent stability.

The commercial opportunity is narrower than for common fillers because the excipient’s value may depend on its functional role rather than its volume contribution. Key development questions include:

• Whether fumaric acid is required for chemical stability.
• Whether its concentration controls dissolution or impurity formation.
• Whether malic acid, citric acid, succinic acid, or another acid can be substituted.
• Whether acid selection changes tablet hardness, hygroscopicity, or long-term stability.

A successful alternative would require comparative stability data, not only acceptable dissolution.

Sodium hydroxide

Sodium hydroxide may be used for pH adjustment during manufacture or formulation processing. Its commercial role is likely functional and low-level rather than structural. It can affect the pH of an aqueous processing phase or support control of the formulation’s microenvironment.

Because sodium hydroxide is a common pharmaceutical material, it is unlikely to create a strong standalone differentiation opportunity. The relevant commercial value is more likely to arise from process control, low-metal grades, validated concentration, and compatibility with the selected manufacturing route.

Film coating

A film coating protects the tablet, improves handling, supports identification, and can affect swallowability. Coating suppliers can compete through:

• Lower coating weight.
• Faster coating cycles.
• Improved pigment dispersion.
• Reduced tablet-to-tablet color variation.
• Lower moisture transmission.
• Ready-to-use aqueous coating systems.
• Compatibility with debossing and high-speed packaging.

Film coating is unlikely to provide meaningful therapeutic differentiation by itself. It can, however, reduce manufacturing cost and improve supply-chain performance.

What excipient opportunities exist for generic EDARBI?

The primary generic opportunity is a conventional immediate-release azilsartan medoxomil tablet. A generic applicant does not need to reproduce every inactive ingredient in the reference listed drug, but the alternative formulation must meet applicable quality, bioequivalence, labeling, and regulatory requirements.

Conventional tablet substitution

The largest opportunity is replacing individual excipients while maintaining:

• Comparable dissolution across relevant pH conditions.
• Comparable assay and content uniformity.
• Acceptable impurity growth under accelerated and long-term stability.
• Suitable hardness and friability.
• Consistent disintegration.
• Adequate process capability at commercial scale.

Potential substitute systems include:

Formulation function	EDARBI-associated approach	Potential alternative
Diluent	Mannitol	Microcrystalline cellulose, lactose, dibasic calcium phosphate
Acidic modifier	Fumaric acid	Citric, succinic, malic, or tartaric acid
Binder	Process-dependent	Copovidone, hydroxypropyl cellulose, povidone
Disintegrant	Process-dependent	Crospovidone, croscarmellose sodium, sodium starch glycolate
Lubricant	Standard tablet lubricant	Magnesium stearate, sodium stearyl fumarate
Coating	Conventional film coat	Ready-to-use aqueous polymer coating

The best commercial strategy is not necessarily to reproduce the reference formulation. It is to identify a simpler, lower-cost or more robust excipient system that meets the target product profile and avoids formulation-specific patent claims.

Excipient supplier opportunity

Excipient suppliers can target generic manufacturers with platforms that offer:

1. Improved flow for direct compression.
2. Lower lubricant sensitivity.
3. Reduced sticking and picking during compression.
4. Faster tablet disintegration.
5. Lower moisture exposure.
6. Better stability under high-temperature and high-humidity conditions.
7. Consistent performance across multiple tablet strengths.

A co-processed excipient may be commercially attractive if it reduces the number of unit operations or improves scale-up. The regulatory benefit is strongest when the components are already used in approved oral solid dosage forms and are supported by FDA precedent.

What formulations could extend EDARBI’s commercial lifecycle?

EDARBI’s immediate-release tablet leaves several formulation pathways open, although each has different commercial value and regulatory complexity.

Orally disintegrating tablet

An orally disintegrating tablet could target patients with dysphagia, older adults, and patients who have difficulty swallowing conventional tablets. Mannitol is compatible with orally disintegrating platforms because it can contribute to mouthfeel and rapid disintegration.

A viable ODT would require control of:

• Mechanical strength.
• Friability during packaging.
• Moisture sensitivity.
• Taste and mouthfeel.
• Disintegration time.
• Dose uniformity.
• Packaging-barrier performance.

Taste masking may be necessary if azilsartan medoxomil or degradation products produce an objectionable taste. This could create formulation patent opportunities, but it would also increase development cost.

Sprinkle or dispersible formulation

A sprinkle formulation could support pediatric or geriatric use. The FDA has approved pediatric use for EDARBI, but the marketed tablet format may not be optimal for all pediatric patients.[1] A dispersible or sprinkle product would need data on dose recovery, administration with food or soft foods, uniformity after dispersion, and stability after opening.

The commercial opportunity is potentially stronger in pediatric markets than in the broad adult hypertension market because patient convenience and adherence can support differentiated pricing.

Fixed-dose combination

Azilsartan medoxomil could be paired with a diuretic or calcium-channel blocker. Combination products can improve adherence and reduce pill burden. The principal development options are combinations with:

• Chlorthalidone or hydrochlorothiazide.
• Amlodipine.
• Other guideline-supported antihypertensive agents.

A combination product creates excipient compatibility issues because the second active ingredient may introduce different pH, moisture, compression, and dissolution requirements. Bilayer tablets, separate-layer tablets, or multiparticulate systems may be necessary if the actives are incompatible.

Modified-release or long-acting systems

Modified release is less commercially compelling for a once-daily antihypertensive unless it provides a measurable clinical or adherence advantage. The formulation burden is higher, and the reference product’s immediate-release profile may limit the addressable market for a premium product.

What patent and exclusivity issues affect EDARBI?

EDARBI is subject to small-molecule generic competition rather than biosimilar competition. Generic applicants would typically file under the ANDA pathway and may submit Paragraph IV certifications against Orange Book-listed patents.[2,3]

Orange Book and patent review

The relevant diligence sequence is:

1. Confirm the current NDA holder and reference listed drug.
2. Review active Orange Book patent listings for NDA 200796.
3. Identify listed patents covering the active ingredient, formulation, method of use, or other approved product attributes.
4. Check patent expiration and pediatric exclusivity dates.
5. Review Paragraph IV litigation and any court-imposed or regulatory stays.
6. Separate listed patents from unlisted formulation and manufacturing patents.

Patent expiration is not equivalent to immediate generic entry. Entry timing can be affected by:

• Paragraph IV litigation.
• Thirty-month stays.
• First-filer 180-day exclusivity.
• Tentative approval.
• Manufacturing readiness.
• FDA review timing.
• Settlement restrictions.
• State-level substitution and market-access contracts.

Formulation and method-of-use patents

The highest-value formulation patents would likely cover:

• Specific excipient ratios.
• Acid-modified compositions.
• Stability-enhancing combinations.
• Coated tablet structures.
• Particle-size or polymorph limitations.
• Pediatric or orally disintegrating formulations.
• Fixed-dose combinations.

Method-of-use patents may cover treatment of hypertension in defined patient populations or dosing regimens. Their commercial value depends on the scope of the claims, the approved labeling, enforceability, and whether a generic can launch with a permissible carve-out.

A generic applicant can often reduce risk by using a non-infringing excipient system, removing protected indications from labeling where legally permitted, or developing a different dosage form. These strategies require claim-by-claim analysis rather than reliance on the reference formulation.

When does EDARBI lose exclusivity?

EDARBI’s regulatory exclusivity has largely expired. The key commercial question is the status of listed patents and any remaining market or settlement barriers, not whether the product still benefits from new-drug exclusivity.

Exclusivity issue	Commercial significance
New chemical entity exclusivity	Expired; EDARBI was approved in 2011
Pediatric exclusivity	Must be checked against the FDA regulatory record and current Orange Book
Patent exclusivity	Depends on active listed patents and expiration dates
Generic pathway	ANDA with Paragraph I, II, III, or IV certification
Biosimilar pathway	Not applicable
First generic launch	Depends on litigation, first-filer status, approval, and commercial readiness

The FDA Orange Book should be treated as the controlling source for current listed patents and exclusivity information.[2] Patent dates should not be inferred from early launch materials because patent-term adjustments, patent-term extensions, terminal disclaimers, and pediatric extensions can change the practical entry date.

Which companies are positioned to challenge or compete with EDARBI?

Competition falls into four groups:

1. Generic azilsartan medoxomil manufacturers.
2. Suppliers of alternative excipient systems.
3. Manufacturers of other angiotensin receptor blockers.
4. Developers of combination and patient-friendly dosage forms.

The closest therapeutic competitors include losartan, valsartan, irbesartan, candesartan, telmisartan, and olmesartan. These drugs have broader generic availability and lower acquisition costs, which limits EDARBI’s ability to command a premium without differentiated clinical, adherence, or contracting advantages.

Generic azilsartan medoxomil would compete primarily on:

• Wholesale acquisition cost.
• Pharmacy substitution.
• Distribution reliability.
• Number of approved strengths.
• Formulary access.
• Manufacturing capacity.
• Ability to avoid or resolve patent litigation.

How strong is the EDARBI patent estate?

The commercial strength of the EDARBI patent estate depends less on the existence of patents than on the remaining enforceable claims and their ability to block a non-infringing immediate-release generic.

A strong estate would contain enforceable claims covering the active pharmaceutical ingredient, commercially necessary salt or prodrug forms, core formulation characteristics, and key uses. A weaker estate would rely primarily on narrow formulation claims that can be designed around through excipient substitution or processing changes.

For excipient developers, the main risk is a claim that captures a functional formulation rather than a named ingredient. Examples include claims directed to a defined pH range, stability profile, dissolution profile, excipient ratio, or manufacturing condition. A substitute formulation should therefore be screened against both composition claims and performance-linked claims.

What generic launch scenarios exist for EDARBI?

Three launch scenarios are commercially relevant.

At-risk Paragraph IV launch

A first filer may launch before final resolution of patent litigation. This can generate high revenue if successful, but it exposes the company to damages, injunction risk, and rapid market disruption if the patent holder prevails.

Authorized or negotiated launch

A settlement may establish a later entry date, license rights, or other commercial terms. The value of the settlement depends on the negotiated launch date, the number of competing ANDA filers, and whether the agreement permits an authorized generic.

Post-expiration launch

Multiple manufacturers may enter after patent expiry or final patent invalidity. This produces rapid price erosion, especially where the product has no strong formulation differentiation and several suppliers are approved.

For excipient suppliers, the most attractive window is usually before ANDA filing, when manufacturers are selecting formulations and locking specifications. Once a formulation is approved, substitution becomes harder because it may require post-approval change control, supplemental filing, stability work, and renewed process validation.

What are the commercial opportunities for EDARBI excipients?

The strongest opportunities are formulation-enabling rather than ingredient-specific.

High-value opportunities

• Co-processed direct-compression systems for low-cost generic tablets.
• Moisture-control systems that improve azilsartan medoxomil stability.
• Fast-disintegrating mannitol platforms for ODT development.
• Ready-to-use film coatings that reduce manufacturing cycle time.
• Pediatric sprinkle or dispersible dosage forms.
• Excipient systems for azilsartan medoxomil fixed-dose combinations.
• Low-risk substitute formulations that avoid listed or unlisted formulation claims.
• Regional supply arrangements for generic manufacturers in the United States, Europe, Japan, and emerging markets.

Geographic coverage

United States opportunities depend on Orange Book status, ANDA filings, Paragraph IV activity, and pharmacy substitution. European opportunities depend on national and centralized procedures, supplementary protection certificate status, and local reimbursement. Japan and other regulated markets may require country-specific bioequivalence, excipient, and manufacturing documentation.

An excipient supplier with global regulatory packages, multiple qualified manufacturing sites, and established DMF support can create more value than a supplier offering only a lower unit price.

Key Takeaways

• EDARBI contains azilsartan medoxomil and is marketed as an immediate-release tablet.
• The disclosed excipient system includes mannitol, fumaric acid, and sodium hydroxide.
• The primary generic opportunity is a conventional tablet using alternative excipients with equivalent quality and bioequivalence performance.
• Mannitol and acid-modification systems provide the most relevant formulation-development opportunities.
• ODT, sprinkle, dispersible, and fixed-dose combination products offer lifecycle opportunities but carry higher regulatory and development costs.
• EDARBI is subject to ANDA and Paragraph IV risks, not biosimilar competition.
• Patent diligence should focus on current Orange Book listings, formulation claims, method-of-use claims, litigation, settlements, and first-filer status.
• Excipient suppliers should engage before generic formulation lock-in, when performance and regulatory support can influence product selection.
• Therapeutic competition from low-cost generic ARBs limits the pricing power of an undifferentiated azilsartan medoxomil product.

FAQs

Is mannitol essential to the EDARBI formulation?

No. A generic manufacturer may use another diluent if the resulting formulation meets quality, stability, dissolution, and bioequivalence requirements. Mannitol may still be preferred because of its established use and processing characteristics.

Can a company develop an EDARBI orally disintegrating tablet?

Yes. An ODT could target patients with swallowing difficulties, but the developer would need to address taste, moisture sensitivity, mechanical strength, packaging, disintegration, and bioequivalence.

Does EDARBI have biosimilar competition?

No. Azilsartan medoxomil is a small-molecule drug. Competition would generally arise through ANDAs and other small-molecule generic pathways.

Can excipient substitution avoid EDARBI formulation patents?

It can reduce risk where claims are limited to specified ingredients or ratios. It may not avoid claims covering functional properties, dissolution characteristics, pH, stability, or manufacturing conditions.

Is a fixed-dose azilsartan medoxomil combination commercially attractive?

Potentially. A combination with a diuretic or calcium-channel blocker could improve adherence and support lifecycle management, but it would face formulation compatibility, regulatory, reimbursement, and competitive pricing challenges.

References

1. U.S. Food and Drug Administration. (2024). Edarbi (azilsartan medoxomil) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards.
4. U.S. Food and Drug Administration. (2019). Inactive Ingredient Database guidance for industry.
5. U.S. Food and Drug Administration. (1995). SUPAC-IR: Immediate release solid oral dosage forms: Scale-up and post-approval changes.